Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults with Overweight or Obesity - Reply

TY - JOUR

T1 - Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults with Overweight or Obesity - Reply

AU - Lingvay, Ildiko

AU - Garvey, W. Timothy

AU - Wadden, Thomas A.

N1 - Funding Information: the National Institutes of Health (NIH) (National Institute on Aging [NIA]). Dr Glymour reported receiving grants from the NIH (NIA, National Institute on Minority Health and Health Disparities, Eunice Kennedy Shriver National Institute of Child Health and Human Development, and National Institute on Alcohol Abuse and Alcoholism) and the Robert Wood Johnson Evidence for Action Program. Funding Information: Conflict of Interest Disclosures: Dr Lingvay reported receipt of grants from Novo Nordisk, Merck, Pfizer, Mylan, and Sanofi; personal fees from Novo Nordisk, Lilly, Sanofi, Merck, AstraZeneca, Janssen, Boehringer Ingelheim, Bayer, Target Pharma, Zealand Pharma, and Intercept; and nonfinancial support from Novo Nordisk, Merck, Boehringer Ingelheim, AstraZeneca, Janssen, Lilly, and Sanofi. Dr Garvey reported serving as site principal investigator for clinical trials sponsored by the University of Alabama at Birmingham that were funded by Novo Nordisk, Pfizer, Eli Lilly, and Epitomee. Dr Wadden reported receipt of personal fees from Novo Nordisk and serving on a scientific advisory board for Novo Nordisk.

PY - 2021/9/28

Y1 - 2021/9/28

UR - http://www.scopus.com/inward/record.url?scp=85115909776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115909776&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.13024

DO - 10.1001/jama.2021.13024

M3 - Letter

C2 - 34581743

AN - SCOPUS:85115909776

SN - 0098-7484

VL - 326

SP - 1214

EP - 1215

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 12

ER -